Cargando…
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
BACKGROUND: The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective Ebola vaccine. METHODS: We undertook 2 phase 1 studies assessing safety and immunogenicity of the viral vector modified vaccinia Ankara virus vectored Ebola Zaire vaccine (MVA-EBO-Z)...
Autores principales: | Venkatraman, Navin, Ndiaye, Birahim Pierre, Bowyer, Georgina, Wade, Djibril, Sridhar, Saranya, Wright, Daniel, Powlson, Jonathan, Ndiaye, Ibrahima, Dièye, Siry, Thompson, Craig, Bakhoum, Momar, Morter, Richard, Capone, Stefania, Del Sorbo, Mariarosaria, Jamieson, Sophie, Rampling, Tommy, Datoo, Mehreen, Roberts, Rachel, Poulton, Ian, Griffiths, Oliver, Ballou, W Ripley, Roman, François, Lewis, David J M, Lawrie, Alison, Imoukhuede, Egeruan, Gilbert, Sarah C, Dieye, Tandakha N, Ewer, Katie J, Mboup, Souleymane, Hill, Adrian V S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452431/ https://www.ncbi.nlm.nih.gov/pubmed/30407513 http://dx.doi.org/10.1093/infdis/jiy639 |
Ejemplares similares
-
Reduced Ebola vaccine responses in CMV(+) young adults is associated with expansion of CD57(+)KLRG1(+) T cells
por: Bowyer, Georgina, et al.
Publicado: (2020) -
CD4 T-Cell Enumeration in a Field Setting: Evaluation of CyFlow Counter Using the CD4 Easy Count Kit-Dry and Pima CD4 Systems
por: Wade, Djibril, et al.
Publicado: (2013) -
Vaccination coverage and immunization timeliness among children aged 12-23 months in Senegal: a Kaplan-Meier and Cox regression analysis approach
por: Mbengue, Mouhamed Abdou Salam, et al.
Publicado: (2017) -
Laboratory and Field Evaluation of the Partec CyFlow MiniPOC for Absolute and Relative CD4 T-Cell Enumeration
por: Wade, Djibril, et al.
Publicado: (2015) -
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
por: Ndiaye, Birahim Pierre, et al.
Publicado: (2015)